Remnant Cholesterol as a Causal Risk Factor for Ischemic Heart Disease: A Mendelian Randomization Study

This Mendelian randomization study used genetic variants associated with non-fasting triglycerides and remnant cholesterol (cholesterol in VLDL, IDL, and chylomicron remnants — the portion of non-HDL cholesterol not in LDL) as instrumental variables in 73,513 individuals from the Copenhagen City Heart Study and Copenhagen General Population Study, to establish whether remnant cholesterol causes ischemic heart disease.

Observational analyses showed that each 1 mmol/L increase in remnant cholesterol was associated with a 2.8-fold increased risk of IHD. Genetic analyses using LPL, APOC3, and APOA5 variants as instruments — which raise remnant cholesterol without affecting LDL-C — confirmed causality: genetically elevated remnant cholesterol was associated with increased IHD risk independent of LDL-C. Importantly, triglyceride-associated variants raised remnant cholesterol without affecting LDL-C, isolating the remnant cholesterol mechanism.

Remnant cholesterol — the cholesterol in triglyceride-rich ApoB-containing lipoproteins (VLDL, IDL, chylomicron remnants) — is atherogenic for the same reason LDL is: it delivers ApoB-containing particles to the arterial wall. In insulin-resistant, high-triglyceride, or metabolic syndrome patients, remnant cholesterol can represent a substantial fraction of total atherogenic particle burden not captured by LDL-C measurement. This Mendelian randomization establishes causality rather than association.

The clinical implication is that non-HDL-C (which captures both LDL-C and remnant cholesterol) more completely characterizes atherogenic burden than LDL-C alone in high-triglyceride patients — and that ApoB, which directly counts all atherogenic particles including remnants, is even more comprehensive.

We rate the evidence strong. A large Mendelian randomization study in 73,513 individuals establishing remnant cholesterol as a causal independent risk factor for ischemic heart disease — foundational evidence for extending lipid risk assessment beyond LDL-C to remnant cholesterol in patients with elevated triglycerides.